Esperion Therapeutics Inc
🇨🇷Costa Rica
- Country
- 🇨🇷Costa Rica
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 240
- Market Cap
- $335.5M
- Website
- http://www.esperion.com
Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk
Phase 3
Completed
- Conditions
- Atherosclerotic Cardiovascular DiseaseHypercholesterolemia
- Interventions
- Drug: placebo
- First Posted Date
- 2016-12-13
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 779
- Registration Number
- NCT02991118
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant
Phase 3
Completed
- Conditions
- HypercholesterolemiaAtherosclerotic Cardiovascular DiseaseStatin Adverse Reaction
- Interventions
- Other: placebo
- First Posted Date
- 2016-12-09
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 345
- Registration Number
- NCT02988115
- Locations
- 🇺🇸
Site 2, Dallas, Texas, United States
🇺🇸Site 1, Dallas, Texas, United States
Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)
Phase 3
Completed
- Conditions
- HypercholesterolemiaAtherosclerotic Cardiovascular Diseases
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2020-05-11
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 2230
- Registration Number
- NCT02666664
A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg
- First Posted Date
- 2016-01-20
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 68
- Registration Number
- NCT02659397
Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension
- First Posted Date
- 2014-06-30
- Last Posted Date
- 2023-04-04
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 143
- Registration Number
- NCT02178098
- Locations
- 🇺🇸
Site 1, Mount Pleasant, South Carolina, United States
🇺🇸Site 2, Mount Pleasant, South Carolina, United States
Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy
Phase 2
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 133
- Registration Number
- NCT02072161
Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002
Phase 1
Completed
- Conditions
- Hyperlipidemia
- Interventions
- Drug: [14C-ETC-1002]
- First Posted Date
- 2014-01-24
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT02044627
- Locations
- 🇬🇧
Quotient Clinical, Nottingham, United Kingdom
Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients
- First Posted Date
- 2013-09-13
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 349
- Registration Number
- NCT01941836
A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia
Phase 2
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- First Posted Date
- 2013-01-30
- Last Posted Date
- 2019-03-29
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT01779453
A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance
- First Posted Date
- 2012-12-18
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Esperion Therapeutics, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT01751984
© Copyright 2025. All Rights Reserved by MedPath